Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017464530> ?p ?o ?g. }
Showing items 1 to 44 of
44
with 100 items per page.
- W2017464530 endingPage "37" @default.
- W2017464530 startingPage "37" @default.
- W2017464530 abstract "The cholesterol-lowering agents, known as statins, have been in use for 15 years and are among the most commonly prescribed drugs. Animal studies and premarketing clinical trials have given signals of hepatotoxicity, primarily minor elevations in serum alanine aminotransferase enzyme (ALT) levels. For that reason, all of the cholesterol-lowering drugs have labeling that requires monitoring of liver enzymes. Postmarketing experience, however, suggests that hepatotoxicity is rare and thus it is timely to revisit the issue. The first of the statins, lovastatin, was approved in 1986 and has acquired 24 million patient-years of clinical experience. Minor elevations in liver enzymes, i.e., ALT 3 x the upper limit of normal (ULN) occur in 2.6% and 5.0% of patients on lovastatin doses of 20 and 80 mg/day, respectively. These elevations are reversible with continuing therapy, are dose related, and are probably related to cholesterol lowering per se. Rare cases of acute liver failure (ALF) have been reported with all of the cholesterol-lowering drugs. With lovastatin, the rate is approximately 1/1.14 million patient-treatment years, which is 9% of the background rate of all causes of ALF and approximately equal to the background rate of idiopathic ALF. Monitoring for hepatotoxicity has not been effective in preventing serious liver disease, largely because of its rarity and the poor predictive value of minor ALT elevations. In fact, it may increase patient risk because of needless discontinuation of cholesterol-lowering therapy for false-positive results in patients who are benefiting from treatment." @default.
- W2017464530 created "2016-06-24" @default.
- W2017464530 creator A5041152397 @default.
- W2017464530 date "2002-11-01" @default.
- W2017464530 modified "2023-09-25" @default.
- W2017464530 title "The liver and lovastatin" @default.
- W2017464530 doi "https://doi.org/10.1016/s1062-1458(02)00916-9" @default.
- W2017464530 hasPublicationYear "2002" @default.
- W2017464530 type Work @default.
- W2017464530 sameAs 2017464530 @default.
- W2017464530 citedByCount "3" @default.
- W2017464530 countsByYear W20174645302012 @default.
- W2017464530 countsByYear W20174645302013 @default.
- W2017464530 crossrefType "journal-article" @default.
- W2017464530 hasAuthorship W2017464530A5041152397 @default.
- W2017464530 hasConcept C126322002 @default.
- W2017464530 hasConcept C2778163477 @default.
- W2017464530 hasConcept C2780940807 @default.
- W2017464530 hasConcept C71924100 @default.
- W2017464530 hasConceptScore W2017464530C126322002 @default.
- W2017464530 hasConceptScore W2017464530C2778163477 @default.
- W2017464530 hasConceptScore W2017464530C2780940807 @default.
- W2017464530 hasConceptScore W2017464530C71924100 @default.
- W2017464530 hasIssue "6" @default.
- W2017464530 hasLocation W20174645301 @default.
- W2017464530 hasOpenAccess W2017464530 @default.
- W2017464530 hasPrimaryLocation W20174645301 @default.
- W2017464530 hasRelatedWork W144874880 @default.
- W2017464530 hasRelatedWork W1987049947 @default.
- W2017464530 hasRelatedWork W2022209180 @default.
- W2017464530 hasRelatedWork W2039318446 @default.
- W2017464530 hasRelatedWork W2050245455 @default.
- W2017464530 hasRelatedWork W2080531066 @default.
- W2017464530 hasRelatedWork W2118567710 @default.
- W2017464530 hasRelatedWork W2748952813 @default.
- W2017464530 hasRelatedWork W2899084033 @default.
- W2017464530 hasRelatedWork W3032375762 @default.
- W2017464530 hasVolume "11" @default.
- W2017464530 isParatext "false" @default.
- W2017464530 isRetracted "false" @default.
- W2017464530 magId "2017464530" @default.
- W2017464530 workType "article" @default.